Cargando…

Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models

PURPOSE: The current study aimed to evaluate the synergistic efficacy of lenvatinib and FOLFOX (infusional fluorouracil (FU), folinic acid, and oxaliplatin) in hepatocellular carcinoma (HCC) using patient-derived xenograft (PDX) and PDX-derived organotypic spheroid (XDOTS) models in vivo and in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Mingxun, Yao, Xinfei, Bo, Zhiyuan, Zheng, Jiuyi, Yu, Haitao, Xie, Xiaozai, Lin, Zixia, Wang, Yi, Chen, Gang, Wu, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065123/ https://www.ncbi.nlm.nih.gov/pubmed/37007211 http://dx.doi.org/10.2147/JHC.S395474

Ejemplares similares

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Association of TNFRSF12A Methylation With Prognosis in Hepatocellular Carcinoma With History of Alcohol Consumption
por: Wang, Yi, et al.
Publicado: (2020)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways
por: Yan, Xijing, et al.
Publicado: (2023)

Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma
por: He, Qikuan, et al.
Publicado: (2022)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation
por: Shi, Zhehao, et al.
Publicado: (2023)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
por: Enomoto, Keisuke, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma: Ferroptosis-related gene model for ICC
por: Yao, Xinfei, et al.
Publicado: (2022)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
por: Tao, Meng, et al.
Publicado: (2023)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma
por: Merle, Philippe
Publicado: (2023)

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2022)

Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib
por: Sato, Aya, et al.
Publicado: (2022)

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro
por: Wang, Xinyue, et al.
Publicado: (2023)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
por: Wang, Cong-Cong, et al.
Publicado: (2023)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Zhu, Jie, et al.
Publicado: (2021)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Ferroptosis, a new form of cell death, and its relationships with tumourous diseases
por: Yu, Haitao, et al.
Publicado: (2016)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis
por: Dong, Dong, et al.
Publicado: (2022)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma
por: Liu, Yulong, et al.
Publicado: (2022)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
por: Shintani, Hiroshi, et al.
Publicado: (2021)

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
por: Rehman, Obaid, et al.
Publicado: (2021)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Lenvatinib-Induced Destructive Thyroiditis in a Patient With Hepatocellular Carcinoma
por: Pandya, Anjani, et al.
Publicado: (2021)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
por: Imakura, Takeshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hlvpac64123nhutv6akcus9f71